Cancer cells in tumors with IDH1 or IDH2 mutations show oncogenic activity by converting glutamine-derived α-KG to 2-hydroxyglutarate (2-HG), which competitively inhibits α-KG-dependent histone and DNA modification enzymes27. Here, IDH2 is linked to cancer.